AAV-TERT-02

AAV-TERT-02 is a preclinical-stage gene therapy candidate being developed by Telomere Therapeutics. The therapy utilizes adeno-associated virus (AAV) vectors to deliver the telomerase reverse transcriptase (TERT) gene into adult tissues. By expressing telomerase, the therapy aims to repair and maintain telomere length, thereby addressing the underlying pathology of diseases caused by telomere shortening and dysfunction. While the specific primary indication for AAV-TERT-02 has not been publicly disclosed, the company's broader focus includes age-related conditions, organ fibrosis, and telomere-dysfunction syndromes. The candidate is currently in the preclinical proof-of-concept stage.